CRSP

60.77

1.81% -1.12

Handel nachbörslich: 60.25 -0.52 -0.86%

Crispr Therapeutics Ag (CRSP)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt CRSP? Forum Prognose

Schlusskurs vom Vortag:

$61.89

Offen:

$62.445

24-Stunden-Volumen:

1.67M

Relative Volume:

0.96

Marktkapitalisierung:

$5.98B

Einnahmen:

$4.10M

Nettoeinkommen (Verlust:

$-568.53M

KGV:

-9.783

EPS:

-6.2118

Netto-Cashflow:

$-401.18M

1W Leistung:

+11.42%

1M Leistung:

+17.23%

6M Leistung:

+4.79%

1J Leistung:

+18.71%

1-Tages-Spanne:

$58.58

$62.80

1-Wochen-Bereich:

$54.56

$63.45

52-Wochen-Spanne:

$44.12

$78.48

Crispr Therapeutics Ag Stock (CRSP) Company Profile

Firmenname

Crispr Therapeutics Ag

Sektor

Healthcare (1094)

Branche

Biotechnology (615)

Telefon

(617) 315-4600

Adresse

BAARERSTRASSE 14, ZUG

Mitarbeiter

393

Twitter

@crisprtx

Nächster Verdiensttermin

2026-08-03

Neueste SEC-Einreichungen

CRSP's Discussions on Twitter

Compare CRSP vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CRSP Crispr Therapeutics Ag	60.77	6.10B	4.10M	-568.53M	-401.18M	-6.2118
VRTX Vertex Pharmaceuticals Inc	522.25	134.41B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	676.23	68.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.94	57.01B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	321.59	41.79B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	190.46	40.39B	742.00K	-1.37B	-1.07B	-7.0731

Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-09-18	Eingeleitet	JP Morgan	Overweight
2025-02-14	Hochstufung	Evercore ISI	In-line → Outperform
2025-02-12	Hochstufung	TD Cowen	Sell → Hold
2025-02-03	Eingeleitet	H.C. Wainwright	Buy
2024-08-06	Bestätigt	Needham	Buy
2024-08-02	Eingeleitet	Rodman & Renshaw	Buy
2024-06-28	Fortgesetzt	Guggenheim	Neutral
2024-02-15	Eingeleitet	Wolfe Research	Peer Perform
2023-12-11	Herabstufung	TD Cowen	Market Perform → Underperform
2023-10-17	Herabstufung	Cantor Fitzgerald	Overweight → Neutral
2023-09-27	Eingeleitet	Mizuho	Buy
2023-08-17	Hochstufung	Citigroup	Neutral → Buy
2023-05-30	Eingeleitet	William Blair	Outperform
2023-04-13	Eingeleitet	Cantor Fitzgerald	Overweight
2023-03-21	Eingeleitet	Bernstein	Mkt Perform
2023-03-17	Eingeleitet	Bryan Garnier	Buy
2023-03-07	Eingeleitet	Robert W. Baird	Neutral
2022-10-11	Eingeleitet	Morgan Stanley	Underweight
2022-08-09	Herabstufung	Barclays	Overweight → Equal Weight
2022-06-23	Herabstufung	Evercore ISI	Outperform → In-line
2022-06-17	Eingeleitet	BMO Capital Markets	Outperform
2022-04-28	Eingeleitet	Credit Suisse	Neutral
2021-12-07	Eingeleitet	Cowen	Market Perform
2021-10-19	Eingeleitet	SVB Leerink	Outperform
2021-06-14	Hochstufung	Citigroup	Sell → Neutral
2021-04-21	Hochstufung	Jefferies	Hold → Buy
2021-03-04	Eingeleitet	JMP Securities	Mkt Outperform
2020-12-10	Bestätigt	Chardan Capital Markets	Buy
2020-12-10	Herabstufung	Jefferies	Buy → Hold
2020-12-10	Bestätigt	Needham	Buy
2020-12-07	Herabstufung	Wells Fargo	Overweight → Equal Weight
2020-10-23	Eingeleitet	RBC Capital Mkts	Sector Perform
2020-10-05	Eingeleitet	BofA Securities	Buy
2020-07-28	Bestätigt	Needham	Buy
2020-07-14	Eingeleitet	SunTrust	Buy
2020-06-15	Bestätigt	Canaccord Genuity	Buy
2020-03-05	Eingeleitet	Stifel	Hold
2020-02-03	Herabstufung	Evercore ISI	Outperform → In-line
2019-11-19	Hochstufung	William Blair	Mkt Perform → Outperform
2019-11-12	Hochstufung	Oppenheimer	Perform → Outperform
2019-08-01	Eingeleitet	Jefferies	Buy
2019-07-26	Eingeleitet	Canaccord Genuity	Buy
2019-06-10	Eingeleitet	ROTH Capital	Buy
2019-04-12	Eingeleitet	Evercore ISI	Outperform
2019-03-14	Eingeleitet	William Blair	Mkt Perform
2019-01-28	Herabstufung	Goldman	Buy → Neutral
2019-01-22	Herabstufung	Citigroup	Neutral → Sell

Alle ansehen

Crispr Therapeutics Ag Aktie (CRSP) Neueste Nachrichten

02:08 AM

Over 2 Billion Reasons to Love CRISPR Therapeutics Right Now - The Motley Fool

02:08 AM

11:36 AM

CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026? - The Motley Fool

11:36 AM

Jul 06, 2026

CRSPCRISPR Therapeutics AG Options - Finviz

Jul 06, 2026

CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool

Jul 06, 2026

CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool

Jul 06, 2026

Citizens reiterates CRISPR Therapeutics stock rating on label expansion potential - Investing.com

Jul 06, 2026

Jul 05, 2026

Does CRISPR Therapeutics’ (CRSP) Russell Index Debut Quietly Reframe Its Biotech Growth Narrative? - simplywall.st

Jul 05, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jul 05, 2026

Jul 03, 2026

CRISPR Therapeutics (CRSP) Price Forecast: Dual Breakout Targets Higher Prices - FXEmpire

Jul 03, 2026

CRISPR Therapeutics (CRSP) Is Up 11.3% After Broad Russell Growth Index Inclusion Has The Bull Case Changed? - Yahoo Finance

Jul 03, 2026

Crispr Therapeutics: Casgevy's Pediatric Win A Trigger For Bullish Sentiment - Seeking Alpha

Jul 03, 2026

Jul 02, 2026

CRSP News | CRISPR THERAPEUTICS AG (NASDAQ:CRSP) - ChartMill

Jul 02, 2026

CRSP Stock Pops As Morgan Stanley Doubles Price Target - timothysykes.com

Jul 02, 2026

Jun 30, 2026

Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know - Yahoo Finance

Jun 30, 2026

Jun 29, 2026

CRISPR Therapeutics AG(NasdaqGM:CRSP) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com

Jun 29, 2026

CRISPR Therapeutics AG(NasdaqGM: CRSP) added to Russell 2500 Growth Benchmark - marketscreener.com

Jun 29, 2026

ETFs Investing in CRISPR Therapeutics AG Stocks - TradingView

Jun 29, 2026

CRISPR Therapeutics AG(NasdaqGM: CRSP) added to Russell 2000 Growth Benchmark - marketscreener.com

Jun 29, 2026

CRISPR Therapeutics AG(NasdaqGM: CRSP) added to Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026

Jun 28, 2026

CRISPR Therapeutics AG(NasdaqGM: CRSP) added to Russell 3000 Growth Benchmark - marketscreener.com

Jun 28, 2026

Jun 27, 2026

CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool

Jun 27, 2026

Price to book forward of CRISPR Therapeutics AG – DUS:1CG - TradingView

Jun 27, 2026

Enterprise value to revenue forward of CRISPR Therapeutics AG – NASDAQ:CRSP - TradingView

Jun 27, 2026

The Best Stocks to Invest $1,000 in Right Now - AOL.com

Jun 27, 2026

Enterprise value to revenue forward of CRISPR Therapeutics AG – DUS:1CG - TradingView

Jun 27, 2026

Enterprise value to EBITDA forward of CRISPR Therapeutics AG – NASDAQ:CRSP - TradingView

Jun 27, 2026

Jun 26, 2026

Enterprise value to EBIT forward of CRISPR Therapeutics AG – NASDAQ:CRSP - TradingView

Jun 26, 2026